Authors
Guillaume Marquis‐Gravel, Amanda Stebbins, Lisa M Wruck, Matthew T Roe, Mark B Effron, Bradley G Hammill, Jeff Whittle, Jeffrey J VanWormer, Holly R Robertson, Jacqueline D Alikhaani, Sunil Kripalani, Peter M Farrehi, Saket Girotra, Catherine P Benziger, Tamar S Polonsky, J Greg Merritt, Kamal Gupta, Thomas E McCormick III, Kirk U Knowlton, Sandeep K Jain, Ajar Kochar, Russell L Rothman, Robert A Harrington, Adrian F Hernandez, W Schuyler Jones
Publication date
2024/2/20
Journal
Journal of the American Heart Association
Volume
13
Issue
4
Pages
e026921
Description
Background
In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to age in atherosclerotic cardiovascular disease.
Methods and Results
In the ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81 mg or 325 mg. The primary effectiveness end point was death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke. The primary safety end point was hospitalization for bleeding requiring transfusion. A total of 15 076 participants were randomized to aspirin 81 mg (n=7540) or 325 mg (n=7536) daily (median follow‐up: 26.2 months; interquartile …
Total citations
20242
Scholar articles
G Marquis‐Gravel, A Stebbins, LM Wruck, MT Roe… - Journal of the American Heart Association, 2024